Tag: Denise Yardley
Novartis breast cancer drug Kisqali plus endocrine therapy extends PFS
Novartis breast cancer drug Kisqali (ribociclib) plus endocrine therapy has succeeded in extending progression-free survival (PFS) compared to only endocrine therapy in three phase 3 ... Read More